# Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT07019090** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** HSK44459

## Key facts

- **NCT ID:** NCT07019090
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-01-19
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07019090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07019090, "Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07019090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*